CEO behind HIV drug Truvada grilled on $3B in profits
02:23
Link copied
Daniel O’Day, the chairman and CEO of Gliead Sciences Inc., is asked to explain U.S. pricing of HIV prevention drug Truvada for PrEP along with his company’s profits and his $30M signing bonus.May 17, 2019
UP NEXT
Parents protest Pride event at Los Angeles elementary school
02:35
Thousands expected at Jerusalem’s Pride parade despite threats of violence
03:33
Uganda president signs anti-gay law that includes death penalty
04:14
Montana becomes first state to ban Drag Story Hours
03:52
Nikki Haley takes aim at transgender influencer Dylan Mulvaney
01:44
Target pulls Pride themed items following anti-LGBTQ threats